» Articles » PMID: 11748284

CD8(+) T Cell-mediated Injury in Vivo Progresses in the Absence of Effector T Cells

Overview
Journal J Exp Med
Date 2001 Dec 19
PMID 11748284
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Tissue injury is a common sequela of acute virus infection localized to a specific organ such as the lung. Tissue injury is an immediate consequence of infection with lytic viruses. It can also result from the direct destruction of infected cells by effector CD8(+) T lymphocytes and indirectly through the action of the T cell-derived proinflammatory cytokines and recruited inflammatory cells on infected and uninfected tissue. We have examined CD8(+) T cell-mediated pulmonary injury in a transgenic model in which adoptively transferred, virus-specific cytotoxic T lymphocytes (CTLs) produce lethal, progressive pulmonary injury in recipient mice expressing the viral target transgene exclusively in the lungs. We have found that over the 4-5 day course of the development of lethal pulmonary injury, the effector CTLs, while necessary for the induction of injury, are present only transiently (24-48 h) in the lung. We provide evidence that the target of the antiviral CD8(+) T cells, the transgene expressing type II alveolar cells, are not immediately destroyed by the effector T cells. Rather, after T cell-target interaction, the type II alveolar cells are stimulated to produce the chemokine monocyte chemoattractant protein 1. These results reinforce the concept that, in vivo, the cellular targets of specific CTLs may participate directly in the development of progressive tissue injury by activating in response to interaction with the T cells and producing proinflammatory mediators without sustained in vivo activation of CD8(+) T cell effectors.

Citing Articles

Opportunities and challenges for T cell-based influenza vaccines.

Mosmann T, McMichael A, LeVert A, McCauley J, Almond J Nat Rev Immunol. 2024; 24(10):736-752.

PMID: 38698082 DOI: 10.1038/s41577-024-01030-8.


Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVID.

Narayanan J, Tamilanban T, Kumar P, Guru A, Muthupandian S, Kathiravan M Arch Microbiol. 2023; 205(6):238.

PMID: 37193831 PMC: 10188327. DOI: 10.1007/s00203-023-03559-z.


Comparisons of lymphocytes profiles and inflammatory cytokines levels in blood of patients with differed severity of infection by human adenovirus type 7.

Sun J, Ma X, Zhang M, Xie M, Zhang X, Han X BMC Infect Dis. 2023; 23(1):174.

PMID: 36949406 PMC: 10031703. DOI: 10.1186/s12879-023-08132-z.


Behavioral and Dietary Habits That Could Influence Both COVID-19 and Non-Communicable Civilization Disease Prevention-What Have We Learned Up to Now?.

Veljkovic M, Pavlovic D, Stojanovic N, Dzopalic T, Popovic Dragonjic L Medicina (Kaunas). 2022; 58(11).

PMID: 36422225 PMC: 9695647. DOI: 10.3390/medicina58111686.


Role of Vitamin A Supplementation in Prevention and Control of Coronavirus Disease-19: A Narrative Review.

Singh N, Chawla H, Kumar A, Singh S Int J Prev Med. 2022; 13:122.

PMID: 36276889 PMC: 9580552. DOI: 10.4103/ijpvm.IJPVM_683_20.


References
1.
Guidotti L, Chisari F . Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001; 19:65-91. DOI: 10.1146/annurev.immunol.19.1.65. View

2.
Ogg G, McMichael A . HLA-peptide tetrameric complexes. Curr Opin Immunol. 1998; 10(4):393-6. DOI: 10.1016/s0952-7915(98)80110-6. View

3.
Wells M, Daniel S, Djeu J, Kiley S, Ennis F . Recovery from a viral respiratory tract infection. IV. Specificity of protection by cytotoxic T lymphocytes. J Immunol. 1983; 130(6):2908-14. View

4.
Enelow R, Mohammed A, Stoler M, Liu A, Young J, Lou Y . Structural and functional consequences of alveolar cell recognition by CD8(+) T lymphocytes in experimental lung disease. J Clin Invest. 1998; 102(9):1653-61. PMC: 509113. DOI: 10.1172/JCI4174. View

5.
Belz G, Altman J, Doherty P . Characteristics of virus-specific CD8(+) T cells in the liver during the control and resolution phases of influenza pneumonia. Proc Natl Acad Sci U S A. 1998; 95(23):13812-7. PMC: 24906. DOI: 10.1073/pnas.95.23.13812. View